New hope for aggressive brain cancer: drug combo shows promise

NCT ID NCT05986851

First seen Apr 12, 2026 · Last updated May 02, 2026 · Updated 2 times

Summary

This study tests a new drug, azeliragon, combined with radiation therapy for people with a specific type of glioblastoma, an aggressive brain cancer. The goal is to see if this combination is safe and can slow cancer growth. About 30 adults with newly diagnosed, unmethylated glioblastoma will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Corewell Health

    Royal Oak, Michigan, 48073, United States

  • Lenox Hill Hospital

    New York, New York, 10021, United States

  • Miami Cancer Institute - Baptist Health

    Miami, Florida, 33176, United States

  • The University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Utah Health Huntsman Cancer Center

    Salt Lake City, Utah, 84112, United States

  • University of Washington

    Seattle, Washington, 98109, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.